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Nephronophthisis (NPHP) is an autosomal recessive cystic kidney disease and a leading genetic cause of established renal
failure (ERF) in children and young adults. Early presenting symptoms in children with NPHP include polyuria, nocturia, or
secondary enuresis, pointing to a urinary concentrating defect. Renal ultrasound typically shows normal kidney size with increased
echogenicity and corticomedullary cysts. Importantly, NPHP is associated with extra renal manifestations in 10–15% of patients.
The most frequent extrarenal association is retinal degeneration, leading to blindness. Increasingly, molecular genetic testing is
being utilised to diagnose NPHP and avoid the need for a renal biopsy. In this paper, we discuss the latest understanding in the
molecular and cellular pathogenesis of NPHP. We suggest an appropriate clinical management plan and screening programme for
individuals with NPHP and their families.
1. Introduction
Nephronophthisis (NPHP) is an autosomal recessive cystic
kidney disease and a leading genetic cause of established
renal failure (ERF) in children and young adults [1]. NPHP
literally means “disappearance of nephrons,” which alludes
to its histopathology, with interstitial fibrosis and corti-
comedullary cysts replacing normal renal tissue. The median
age of an aﬀected child with ERF is 13 years [2]. The inci-
dence of NPHP varies worldwide; it was previously identified
to range from 1 in 50,000 to 1 in 900,000 [3–5]; however,
these figures are likely to underrepresent the true frequency,
since molecular testing has diagnosed NPHP in adults pre-
senting with advanced chronic kidney disease (CKD) [6, 7].
The prevalence of NPHP amongst the paediatric population
with ERF is 5% in the USA [2] and 6.5% in the UK [8, 9].
Early presenting symptoms in children with NPHP
usually develop at around 6 years of age and include polyuria,
nocturia or secondary enuresis, polydipsia, and lethargy (sec-
ondary to anaemia) [10]. These features are a consequence
of salt wasting and an inability to concentrate urine
(<400mosm/kg early morning urine), implicating dysfun-
ction of the renal cortical collecting duct [11]. Renal ultra-
sound identifies normal or reduced kidney size, with in-
creased echogenicity and corticomedullary cysts [2]. There
is a less common infantile variant of NPHP in which
children reach ERF by 3 years of age and have enlarged
cystic kidneys on renal ultrasound [12]. Infantile NPHP is
distinct from autosomal recessive polycystic kidney disease
(ARPKD). There is a diﬀuse distribution of cysts within
the kidneys of children with ARPKD, and it is more often
associated with liver cysts and fibrosis [13]. A diagnostic
renal biopsy of NPHP reveals a characteristic triad of
tubular basement membrane disruption, tubulointerstitial
nephropathy/fibrosis, and corticomedullary cysts [4, 14].
Increasingly, molecular genetic testing [15] is being utilised
to diagnose NPHP and avoid the need for a renal biopsy [16].
NPHP is associated with extra renal manifestations in
10–15% of patients [1]. The most frequent anomaly is
retinal degeneration; other associated features and disorders
include cerebellar vermis hypoplasia (Joubert Syndrome
(JS)), occipital encephalocele (Meckel-Gruber syndrome
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(MKS)), hepatic fibrosis, situs inversus, bronchiectasis, and
skeletal defects [1]. In addition to this apparent variability in
the spectrum and severity of phenotype, NPHP is genetically
heterogenous. To date mutations have been identified in 13
genes (Table 1) which collectively account for approximately
30% of patients [17]. The protein products of all of these
genes localise on primary cilia and related structures (basal
bodies, centrosomes), resulting in a unifying hypothesis that
cystic kidney diseases are ciliopathies [18]. In this paper, we
will discuss the latest understanding in the molecular and
cellular pathogenesis of NPHP and suggest an appropriate
management plan/screening programme for individuals and
their families, particularly in view of the considerable clinical
heterogeneity.
2. Molecular and Genetic Pathogenesis
NPHP is a recessive monogenic disorder [19], meaning that
two mutations (homozygous or compound heterozygous)
in a single gene are suﬃcient to cause disease [20]. Thir-
teen genes have been identified in aﬀected families with
NPHP (Table 1), and these genes currently allow 30% of
patients with NPHP to be “solved” in terms of a molecular
diagnosis. These genes have been identified using positional
cloning strategies and homozygosity mapping in consan-
guineous families [20]. Subsequent localisation of all these
encoded proteins, termed “nephrocystins,” to the primary
cilium/basal body led to recognition of NPHP as a ciliopathy
[17]. Primary cilia are highly conserved, microtubule-based
hair-like structures which extend from the apical surface of
almost every epithelial cell. They function in order to detect
extracellular cues and mediate cellular signalling pathways
(discussed below) [13]. Ciliary genes are currently recognised
as attractive candidates to evaluate when attempting to define
the molecular cause of NPHP in the presently undiagnosed
70% of patients. With this in mind, combined homozy-
gosity mapping, ciliopathy candidate exome capture, and
parallel sequencing have recently been performed resulting
in the successful identification of pathological mutations
in the gene, serologically defined colon cancer antigen 8
(SDCCAG8), in families with NPHP [21]. SDCCAG8 is
synonymous withNPHP10. Also recently, the targeted screen
of the ciliary gene TTC21B revealed that its protein product,
IFT139, is essential for retrograde intraflagellar transport.
IFT139 interacts with ciliopathy proteins BBS4 and BBS8,
and pathogenic mutations in TTC21B were identified in
patients with NPHP and more severe related ciliopathies
[22].
Although the majority of currently known NPHP genes
produce proteins which localise to primary cilia/basal bod-
ies/centrosomes, recent identification of an NPHP-like locus
in two aﬀected families suggests that NPHP genes may
not be exclusively ciliary [35]. Genome-wide homozygos-
ity mapping identified pathogenic mutations in X-prolyl
aminopeptidase 3 (XPNPEP3), or NPHPL1 (NPHP like 1
gene), of which the protein product localises tomitochondria
[35]. Although not currently identified in the primary
cilium, XPNPEP3 may influence cilia function through
enzymatic cleavage of associated ciliary proteins [35].
Whilst homozygous mutations in the NPHP genes can
cause isolated NPHP, mutations in the same gene can
be pleiotropic inducing a spectrum and variable severity
of phenotypes. Similarly, it would appear logical that
the type of mutation may influence the phenotype. For
example, a missense mutation may cause isolated NPHP or
Senior-Loken syndrome (SLS, retinitis pigmentosa), whilst a
truncating mutation could cause MKS. Recently the eﬀect
of diﬀerent mutations in NPHP6 on clinical presentation
has been eloquently reviewed [36]. Furthermore, some
NPHP genes are more likely to be associated with certain
extrarenal features. The concept of “modifier genes” has been
recognised in patients with the related ciliopathy, Bardet-
Biedl syndrome (BBS), where pathogenic mutations in more
than one gene have been detected, implicating a role for
oligogenicity [37]. Oligogenicity or triallelism, whereby a
mutation in a third allele may exert an epistatic eﬀect and
modify the phenotype, has been described in NPHP [38]. A
brief description of each of the NPHP genes, their encoded
nephrocystin proteins, and any interacting protein partners
is given below.
2.1. NPHP1 and Nephrocystin-1. NPHP1 was the first NPHP
gene identified and accounts for the majority (20–25%) of
known cases of isolated NPHP [23, 24]. Recently adults
presenting with signs of NPHP and ERF in two generations
of a Turkish family with no known consanguinity suggested
a diagnosis of a dominant cystic kidney disease such as
medullary cystic kidney disease (MCKD) or perhaps a
novel variant of dominant NPHP [7]. However, identifi-
cation of homozygous mutations in NPHP1 in all aﬀected
family members revealed a pseudodominant inheritance of
unknown cause as a consequence of unidentified consan-
guineous relationships. The increased age at presentation
with ERF is atypical and is hypothesised to be a consequence
of currently unknown modifier genes [7].NPHP1mutations
can also cause retinal and cerebellar phenotypes leading
to SLS and JS. Oligogenicity has been reported in families
with NPHP, where mutations in both NPHP1 and NPHP3,
NPHP1 and NPHP4 [38], and NPHP1 and the ciliopathy
gene Abelson helper integration site-1 (AHI1, the most
frequently mutated gene in JS [39]) have been detected [40].
Mutations in both NPHP1 and NPHP6 have been identified
in patients with NPHP-related ciliopathies including SLS
and JS [41]. This evidence of genetic interaction, known
protein-protein interactions between various nephrocystins,
combined with an awareness of other ciliary proteins
such as BBSome functioning as a complex [13], makes
it highly likely that several of the nephrocystins form a
functional supramolecular complex within cells [17, 20].
Nephrocystin-1 localises at cell-cell contacts including tight
junctions, adherens junctions, and focal adhesions [42, 43].
Nephrocystin-1 has also been identified at the transition
zone/base of the primary cilium [44]. Nephrocystin-1 inter-
acts with various other proteins important in maintaining
the cellular scaﬀolding or cytoskeleton including jouberin
[45], ack1 [46], filamin A and B, tensin (actin binding), β-
tubulin (microtubule structure), and protein tyrosine kinase
2B (PTK2B) [20].
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Table 1: Mutated genes in nephronophthisis and associated extrarenal manifestations.
Locus Gene Chromosome Protein
Mutation
frequency [20]
Extrarenal features Ref.
NPHP1 NPHP1 2q13 Nephrocystin-1 23% SLS, JS, [23, 24]
NPHP2 INV 9q31 Inversin 1-2%
SLS, HF VSD, situs
inversus
[25]
NPHP3 NPHP3 3q22.1 Nephrocystin-3 <1%
SLS, HF, MKS, situs
inversus
[26]
NPHP4 NPHP4 1p36.22
Nephrocystin-4 or
nephroretinin
2-3% SLS [27, 28]
NPHP5 IQCB1 3q21.1
Nephrocystin-5 or IQ motif
containing B1
3-4% SLS [29]
NPHP6 CEP290 12q21.32 Centrosomal protein 290 1%
LCA, SLS, JS, MKS,
BBS
[30]
NPHP7 GLIS2 16p13.3 GLI similar 2 <0.5% [31]
NPHP8 RPGRIP1L 16q12.2 RPGRIP1-like 0.5% SLS, JS, MKS [32]
NPHP9 NEK8 17q11.1 NIMA-related kinase 8 <0.5% SLS [33]
NPHP10 SDCCAG8 1q44
Serologically defined colon
cancer antigen 8
<0.5% SLS, BBS-like [21]
NPHP11 TMEM67 8q22.1 Transmembrane protein 67 <0.5% JS, HF, MKS [34]
NPHPL1 XPNPEP3 22q13 X-prolyl aminopeptidase 3 <0.5%
cardiomyopathy,
seizures
[35]
TTC21B 2q24.3
Intraflagellar transport
protein 139
<1% JS, MKS, BBS, JATD [22]
BBS: Bardet-Biedl syndrome; HF: hepatic fibrosis; JATD: Jeune asphyxiating thoracic dystrophy; JS: Joubert syndrome; LCA: Leber’s congenital amaurosis;
MKS: Meckel-Gruber syndrome; SLS: Senior-Loken syndrome; VSD: ventricular septal defect.
2.2. NPHP2/INVS and Inversin. Mutations in NPHP2 are
distinct because they cause infantile NPHP, characterised
by an earlier presentation of ERF (at approximately 3 years
of age), with enlarged kidneys on ultrasound. Additional
clinical features include cardiac anomalies (situs inversus
and ventricular septal defects (VSD)) [47]. AlthoughNPHP2
mutations are a rare cause of NPHP compared to NPHP1,
there has been intense research regarding the molecu-
lar/cellular pathogenesis of inversin. Inversin is located in
the primary cilium and other subcellular sites in a cell-
cycle dependent manner [48]. A previous work has suggested
that inversin acts as a switch between canonical and non-
canonical (planar cell polarity) Wnt signalling [49]. When
inversin is lost after NPHP2 mutation, it was proposed that
sustained canonical Wnt signalling led to cell proliferation
and random oriented cell division [49]. However, recent
experiments in the inv mutant mouse model of NPHP
showed no diﬀerence in canonical Wnt signalling compared
to controls [50]. In addition to nephrocystin-1, inversin
interacts with calmodulin, catenins, β-tubulin [25], and
anaphase-promoting complex 2 [48, 51].
2.3. NPHP3 and Nephrocystin-3. Mutations in NPHP3 are
again a rare cause of isolated NPHP; however, they can
cause a broad spectrum of phenotypes as shown in Table 1.
Nephrocystin-3 colocalises with nephrocystin-1 [26] and
inversin [52] in primary cilia, adherens junctions, and focal
adhesions [20]. The pcy mouse model of NPHP displays
cystic kidneys and responded to treatment with aquaretic
agents/vasopressin-2-receptor antagonists [53].
2.4. NPHP4 and Nephrocystin-4/Nephroretinin. Individuals
with mutations in NPHP4 most frequently have an associ-
ated retinal phenotype [54]. Nephrocystin-4 colocalises and
interacts with nephrocystins 1, 3 and inversin in primary
cilia and associated appendages, adherens junctions, and
focal adhesions [20, 27]. Nephrocystin-4 also interacts with
nephrocystin-8 [55, 56], α-tubulin, breast cancer antioe-
strogen resistance 1 (BCAR1), PTK2B [20], and the tight
junction proteins PALS1/PATJ/Crb3 which are required for
epithelial morphogenesis [57].
2.5. NPHP5/IQCB1 and Nephrocystin-5. NPHP5 mutations
are associated with early onset retinal degeneration, SLS [29].
Nephrocystin-5 contains two IQ calmodulin binding sites;
the significance of its interaction with calmodulin is unclear.
It colocalises with nephrocystin-1 and nehrocystin-4 in the
primary cilium, adherens junctions, and focal adhesions [29]
and interacts with nephrocystin-6 [30, 58]. Nephrocystin-
5 also complexes with the retinal ciliopathy gene retinitis
pigmentosa GTPase regulator (RPGR) [29], explaining the
frequent retinal phenotype.
2.6. NPHP6/CEP290 and Nephrocystin-6. Mutations in
NPHP6 cause a full spectrum of extrarenal features with no
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apparent genotype-phenotype correlation [36]. It is the
commonest genetic cause (21%) of isolated congenital retinal
degeneration, Leber’s congenital amaurosis (LCA) [59]. It
was suggested that oligogenicity and the eﬀect of modifier
genes may account for some of the pleiotropy. Oligogenicity
has been described in patients with homozygous NPHP6
mutations and an additional heterozygous mutation in:
NPHP4 resulting in NPHP [36] or SLS [54], NPHP11
causing BBS or MKS [60], and AHI1 causing JS [41].
Oligogenicity has also been identified in patients with SLS
and JS as a consequence of a homozygous mutation in
NPHP1 and heterozygous mutation in NPHP6 [41]. NPHP6
interacts with and modulates the transcription factor ATF4,
involved in cAMP-dependent renal cyst formation [30]. In
addition to nephrocystin-5 [58], another protein interaction
partner of nephrocystin-6 is coiled-coil and C2 domain
protein (CC2D2A) [61]. In zebrafish models of combined
NPHP6 and CC2D2A knockdown, there is synergy of the
renal cystic phenotype, suggesting an epistatic, disease-
modifying eﬀect [61]. CC2D2A mutations cause JS and MKS
[62]; however, they have not been identified in patients with
isolated NPHP [15, 61].
2.7. NPHP7/GLIS2 and GLIS2. NPHP7 is a rare cause of
isolated NPHP [31]; its protein product is a Kruppel-
like zinc-finger transcription factor, Gli-similar protein 2,
which localises to the primary cilium and nucleus [31].
Interestingly, a Glis2 knockout mouse model showed an
upregulation of genes promoting epithelial-to-mesenchymal
transition and histological features of NPHP including
fibrosis [31]. This correlation of nephrocystin-7 with GLI
transcription factors links the pathogenesis of NPHP to the
Hedgehog (Hh) signalling pathway, which is essential for
controlling tissue maintenance [63].
2.8. NPHP8/RPGRIP1L and RPGRIP1L. NPHP8 mutations
more frequently cause extrarenal manifestations such as
cerebello-oculo-renal syndromes, JS [32, 56], and MKS [56]
than isolated NPHP. There appears to be some genotype-
phenotype correlation with missense mutations causing LCA
[64], whilst truncating mutations cause the more severe dis-
order MKS [56]. RPGRIP1L colocalises with nephrocystin-
4 and nephrocystin-6 at basal bodies and centrosomes [56].
RPGRIP1L interacts with nephrocystin-1 and nephrocystin-
4 [20].
2.9. NPHP9/NEK8 and NEK8. NPHP9 mutations are a
rare cause of both infantile and noninfantile NPHP [33].
Oligogenicity has been identified with a pathogenic homozy-
gous mutation in NPHP5 and heterozygous NPHP9 muta-
tion, which may behave as a modifying gene, in an indi-
vidual with SLS [33]. In some patients with heterozygous
NPHP9mutations, a second recessive mutation has not been
identified. Its protein product, never in mitosis A-related
kinase 8 (NEK8), colocalises with various nephrocystins in
primary cilia, basal bodies, and centrosomes and appears
to be important in regulating the cell cycle [20]. NEK8
has been shown to interact with polycystin-2 (autosomal
dominant polycystic kidney disease (ADPKD) protein), to
regulate its expression and phosphorylation [65]. NEK8
may thus function in a protein complex with polycystin 1
and 2.
2.10. NPHP10/SDCCAG8 and SDCCAG8. SDCCAG8 was
recently identified as NPHP10 by homozygosity mapping,
ciliopathy candidate exome capture, and parallel sequencing
[21]. Twelve mutations were identified in ten families
with NPHP-related ciliopathies, in particular SLS and BBS.
Homozygous SDCCAG8 mutations account for 3.3% of
cases of SLS. Its protein product, serologically defined colon
cancer antigen 8 (SDCCAG8), colocalises at centrosomes
and cell-cell junctions with nephrocystin-5. SDCCAG8 and
nephrocystin-5 colocalise in the transition zone of pho-
toreceptors which is likely of functional significance and
correlates with the phenotype of SLS. SDCCAG8 also colo-
calises with the retinal ciliopathy proteins RPGRIP and RP1.
SDCCAG8 interacts directly with the protein oral-facial-
digital syndrome 1 (OFD1) [21], although the functional
significance of this is currently not clear, it is clearly of
interest, as recessive mutations in OFD1 are an X-linked
cause of the NPHP-related ciliopathy JS [66].
2.11. NPHP11/TMEM67/MKS3 and TMEM67. Mutations
in NPHP11 are pleiotropic, having been identified in
patients with NPHP and liver fibrosis, extending to patients
with related ciliopathies including JS, MKS [34], and
COACH syndrome (cerebellar vermis hypoplasia, oligophre-
nia (developmental delay), ataxia, coloboma, and hypotonia)
[67]. Whilst oligogenicitiy has not been described, a patient
with JS and an isolated heterozygous NPHP11 mutation has
been identified [68], suggesting that triallelism and the role
of NPHP11 as a modifier gene is possible. Transmembrane
protein 67 (TMEM67) or meckelin localises to the mem-
brane of primary cilia and diﬀusely at basal and basolateral
cell surfaces [69]. TMEM67 interacts with several proteins
including nesprin 2 [70], MKS1 [69], and TMEM216 [71]
which are important in maintaining cellular structure and
mitigating centrosome migration, which is essential for
ciliogenesis.
2.12. NPHPL1/XPNPEP3 and XPNPEP3. NPHP-like 1 gene
(NPHPL1) was recently identified in two consanguineous
families with NPHP by genome-wide homozygosity map-
ping [35]. Additional extrarenal manifestations include
cardiomyopathy and seizures. This is a novel discovery
because it is the first NPHP gene identified whose protein
product, X-propyl aminopeptidase 3 (XPNPEP3), does not
localise to primary cilia, basal bodies, or centrosomes [35].
Instead, XPNPEP3 localises in mitochondria; however, it
has been hypothesised that this enzyme may be able to
interfere with cilia function by cleaving certain cilial proteins
[17, 35].
2.13. TTC21B and IFT139. Mutations in TTC21B have
recently been identified in families with isolated NPHP
and extrarenal manifestations including the ciliopathy, Jeune
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asphyxiating thoracic dystrophy (JATD) [22]. Interestingly,
both causal mutations (homozygous or compound heterozy-
gous) and modifier mutations (heterozygous) in TTC21B
were identified in aﬀected individuals. Oligogenicity was
identified between TTC21B and several other ciliopathy
genes. With regard to NPHP, triallelism was identified in a
Turkish family with mutations in both TTC21B and NPHP4.
The protein product of TTC21B is a retrograde intraflagellar
transport protein IFT139, found in the primary cilium, and
is essential for ciliary function.
3. Oligogenicity and Modifier Genes
Oligogenicity has been described above for NPHP1, NPHP5,
NPHP6, NPHP8, NPHP9, NPHP11, and TTC21B. It has been
hypothesised that oligogenicity may help to account for the
intrafamilial variation in age of onset of ERF and severity of
clinical features [38]. Current evidence fails to consistently
identify a correlation between genotype and phenotype
[17], therefore mutation analysis is required to identify
the molecular cause. Making a molecular diagnosis often
involves expensive and time-consuming mutation analysis.
However, the results may be important when managing
patients, to guide appropriate screening for potentially
associated complications of the retina, cerebellum, liver and
lungs. Understanding the natural history of NPHP and
associated complications will hopefully improve following
completion of the current clinical trial ongoing in France,
which is evaluating the evolution of NPHP and related
extrarenal manifestations in children (over 7 years of age)
with a confirmed diagnosis of NPHP1–8 (excluding NPHP7)
(see http://clinicaltrials.gov/ct2/show/NCT01022957?term=
nephronophthisis&rank=1). The results of this study may
facilitate understanding in characterising genotype/pheno-
type associations. Although NPHP-related ciliopathies are
heterogenic disorders, the true frequency of oligogenicity
remains uncertain. It is however interesting that mutation
analysis of 18 NPHP associated ciliopathy disease genes
(including 12 NPHP genes, SDCCAG8 was not included) in
120 patients with NPHP and related ciliopathies, using DNA
pooling and next generation sequencing, recently failed to
identify any evidence of oligogenicity [15]. Remarkably, in
75% of patients in this cohort, no mutations were detected
in the known candidate NPHP genes [15].
Since the molecular cause of NPHP remains unidentified
in 70–75% of cases, it is anticipated that additional NPHP
genes will be discovered. Whilst genes involved in the struc-
ture and function of the primary cilium are logical candidates
to consider, indeed this approach has resulted in the recent
successful identification of TTC21B [22], it is interesting that
“noncilial” causal genes such asXPNPEP3 [35] are now being
identified. Additionally, genes implicated in maintaining the
cell cytoskeleton and cellular junctions are likely involved.
Whilst identifying causal genes is fundamental to determine
the pathogenesis of NPHP, it is the tip of the iceberg
and we need to understand the functional consequences of
such mutations within tissues. We will now discuss current
hypotheses for the cellular pathophysiology of NPHP.
4. Cystic Kidney Disease as a Ciliopathy
In 2005, realisation that polycystin-1 and polycystin-2 (pro-
tein products of ADPKD genes PC1 and PC2) and the
discovered nephrocystins (NPHP1–5) were all expressed
in the primary cilium, basal body, and centrosomes led
to consideration of the term “ciliopathy” as a unifying
theory for cystic kidney disease [18]. A few years earlier,
the concept of a ciliopathy, a disorder in which abnormal
structure or function of cilia/centrosomes is associated with
defective proteins encoded by mutated genes, was attributed
to the multisystem disorder BBS [72]. In the intervening
years, the primary cilium [73] had been extensively studied.
Primary cilia are composed of an axoneme containing
nine microtubular doublets which extend by a process of
intraflagellar transport (IFT) and mediate the traﬃcking of
signals between the extra- and intracellular environments
[73]. Cilia are considered to be involved in mechanosensa-
tion of urinary flow in the renal tubules [74].
Normally, in healthy kidneys, the renal cortical col-
lecting duct (CCD) concentrates urine by responding to
vasopressin, which binds to vasopressin-2 receptors (V2R).
V2R are coupled to adenylyl cyclase resulting in increased
intracellular cyclic AMP (cAMP), leading to phosphorylation
of aquaporin-2 water channels (AQP2), which mediate water
reabsorption [11]. In NPHP, inability to concentrate urine
is the earliest clinical feature and is unresponsive to desmo-
pressin therapy [10]. In animal models of NPHP, vasopressin
levels are elevated and thought to contribute to cystogenesis
by upregulating cell proliferation [75]. Identification of
V2R in the primary cilium of renal epithelial cells [76]
is consistent with the theory of cystic kidney diseases as
ciliopathies. This also emphasises the importance of the
primary cilium in water reabsorption which has recently
been eloquently investigated in patients and renal epithelial
cell culture models of the related ciliopathy BBS [77].
Understanding the pathogenesis of this urine concentration
defect should help explain the success of vasopressin receptor
antagonists in animal models of NPHP, where they induced
a reduction in cAMP levels and caused regression of cysts
[53].
In NPHP, in response to urinary flow, cilia are considered
to alter expression of inversin and potentially influence
Wnt signalling pathways and planar cell polarity [17, 78].
Originally, observations inmousemodels established the link
between primary cilia and cystic kidney disease: the orpk
mouse model of ARPKD with a Tg737 mutation (disrupting
the protein polaris) has impaired ciliogenesis and renal cysts
[79].
The extrarenal manifestations of NPHP including retinal
degeneration and SLS, usually associated with NPHP5 and
NPHP6 mutations, can be explained by ciliary dysfunc-
tion. Retinal photoreceptors contain a connecting cilium
through which rhodopsin traﬃcs along, mediating photo-
sensation [18]. Both nephrocystin-5 and -6 are expressed
in the connecting cilia of retinal photoreceptors and dis-
rupted structure or function of these proteins interferes
with rhodopsin transport, leading to retinal degeneration
(17, 20).
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Through their involvement in various cellular signalling
pathways including Hh, calcium, and Wnt, cilia mediate sev-
eral fundamental processes including cell cycle, proliferation,
diﬀerentiation, and polarity [73]. Proposed mechanisms
for renal cystogenesis include abnormal cell proliferation,
fluid secretion, and disorientated cell division leading to
cystic expansion rather than longitudinal tubular growth
[78]. However, aberrations in the signalling pathways link-
ing cilia to cystogenesis remain incompletely understood,
complicated by sometimes contradictory evidence. A recent
helpfulreview of mechanisms of NPHP discusses each gene
[17]. Here we provide an overview, concentrating on theWnt
signalling pathway.
5. Wnt Signalling and NPHP
Wnt signalling involves several ciliary proteins including
PC1, PC2, inversin, nephrocystin-3, jouberin, BBS1, BBS4,
BBS6, OFD1, and HNF1β, to regulate cell proliferation and
diﬀerentiation [80]. It is composed of two pathways: canon-
ical (β-catenin dependent) and noncanonical (or planar
cell polarity (PCP)); the functional branch appears to be
determined in part by inversin acting as a switch at the base
of the primary cilium [49]. Interestingly, both over activation
[49, 81] and underactivation [82] of the canonical Wnt
pathway have been identified in animal models of NPHP
and JS, suggesting that unbalanced canonical Wnt signalling
is damaging and mediates cystogenesis [80]. However, this
theory has recently been refuted by studies in the inv
mouse model of NPHP, where no change in canonical Wnt
signalling was identified between cystic inv mutants and
controls [50].
PCP describes the normal intrinsic organisation of cells
in a tissue plane perpendicular to their apicobasal polarity
[83]. PCP regulates kidney tubule development or recovery
from injury by convergent extension and orientated cell
division [78, 84], meaning that cells are spatially orientated
and divide along an axis to maintain a constant tubule
diameter whilst elongating [78, 85]. Several mouse models
of cystic kidney disease provide evidence of aberrant PCP
signalling [83, 86]. An excellent, comprehensive review of
the role of Wnt signalling in cystic kidney disease has been
published recently [80].
The other signalling pathway with particular relevance
to understanding the pathophysiology of NPHP is the Hh
pathway. An association with NPHP was realised when Hh
eﬀector proteins, GLI transcription factors, were noted to
be related to GLIS2, the protein product of NPHP7. Loss
of GLIS2 promotes epithelial to mesenchymal translation
(EMT), fibrosis and apoptosis, and histological hallmarks of
NPHP [31]. Thus although NPHP7 is a rare cause of NPHP,
its discovery has contributed important understanding to the
signalling pathways involved.
6. Clinical Management of NPHP
6.1. Diagnosis and Investigations. In order to establish a
clinical diagnosis of NPHP, a detailed history, clinical
Table 2: NPHP genes available for testing via UK and European
gene testing networks.
Gene Laboratory
NPHP1 NE Thames, London
NPHP1 Glasgow, Scotland
NPHP1 Utrecht, Netherlands
NPHP1 Helsinki and Tampere, Finland
NPHP1 Malaga, Spain
NPHP1 Granada, Spain
NPHP1,2 Gosselies, Belgium
NPHP1,2 Brussels, Belgium
NPHP1–3 Aachen, Germany
NPHP1–4 Paris, France
NPHP1–4 Weißwasser, Germany
NPHP1–4 Tubingen, Germany
NPHP1–4, 7 Rostock, Germany
NPHP1–4, –9, NPHPL1 Barcelona, Spain
NPHP1–4, –9, NPHPL1 Oviedo, Spain
NPHP1–4, –9, NPHPL1 Leuven, Belgium
NPHP1–4, 6–9 Ingelheim, Germany
examination, including looking for extrarenal associations
(abnormal eye movements, retinopathy, ataxia, polydactyly,
and cardiac malformations) is required. A detailed family
history must be taken both to facilitate diagnosis and
to highlight other individuals who should be invited for
review. Appropriate investigations include renal and liver
function tests; urine concentration ability, renal and hepatic
ultrasound, cerebral imaging if clinically indicated, and
referral to an ophthalmologist (Figure 1) [16]. After genetic
counselling, bloodmay be sent for genetic testing (Table 2) to
genetic testing organisations (e.g., http://www.ukgtn.nhs.uk/
or http://www.eurogentest.org/) to seek a molecular diag-
nosis. Regular review is required to appropriately manage
CKD/ERF, and individuals with extrarenal manifestations
should be referred to appropriate colleagues and are ideally
best managed in specialist clinics.
6.2. Treatment. Presently there is no cure for NPHP and
related ciliopathies. Clinicians must focus on optimising
the delivery of renal replacement therapy, ideally with renal
transplantation where possible. However with a growing
understanding of the pathophysiology of NPHP, the future
is more hopeful. In recent years various drugs including
vasopressin receptor antagonists [53], mTOR inhibitors
(mammalian target of rapamycin) [87], triptolide [88] and
roscovitine (cyclin-dependent kinase inhibitor) [89] have
been shown to be eﬀective in reducing renal cysts in animal
models of NPHP and ADPKD. Many of these drugs are
currently or have recently been involved in clinical trials in
adult patients. Furthermore, large numbers of compounds
which could be potential therapies are being screened in
zebrafish [90] models of ciliopathies.
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Presentation suggestive of NPHP
Urine concentration defect:
polydipsia, polyuria, enuresis,
salt wasting
Renal ultrasound: normal or
small kidney size, hyperechogenic,
corticomedullary cysts
Family history of consaguinuity
or autosomal recessive pattern of
inheritance of ERF
Examination
(evaluate for associated extra renal
manifestations)
Blood pressure, assess fluid
balance, abdominal (palpate liver,
kidneys)
Neurological: eye movements,
fundoscopy, cerebellar assessment
Cardiovascular
/respiratory
Skeletal: accessory
digits
Investigations
(if indicated and not already performed)
Blood tests: FBC,
Coag, Iron, UE, bone
profile, Mg, urate
Urinalysis:
blood, protein,
osmolality
Ultrasound:
kidneys, liver
Cerebral
imaging: MRI
Renal biopsy:
rarely
Consider
ophthalmology referral
Differential diagnosis
NPHP, ARPKD, JS, BBS
Genetic counselling and testing
for molecular diagnosis
Management of
CKD/workup for RRT
Regular review for
associated extra renal
manifestations
Invite further family
members for review if
appropriate
Figure 1: Diagnostic algorithm for suspected cases of NPHP. ARPKD: autosomal recessive polycystic kidney disease; BBS: Bardet-Biedl
syndrome; CKD: chronic kidney disease; Coag: coagulation; ERF: established renal failure; FBC: full blood count; JS: Joubert syndrome;
LFT: liver function tests; Mg: magnesium; MRI: magnetic resonance imaging; NPHP: nephronophthisis; RRT: renal replacement therapy;
UE: urea and electrolytes.
7. Conclusion
Understanding of the molecular genetics of NPHP has
advanced considerably over the last few years. We are increas-
ingly aware of the heterogeneity, the pleiotropic nature of
mutations, and oligogenicity, all of which contribute to the
complexity of NPHP. Identification of further NPHP genes,
many of which may be “ciliary,” is warranted to provide fur-
ther clues to its pathogenesis. This will require international
multidisciplinary collaboration to sequence patient cohorts
with no current molecular diagnosis and to screen candidate
genes in animal and cell models. Acknowledgement that the
genetic cause is unknown in 70% of NPHP cases, combined
with awareness that a mitochondrial gene, XPNPEP3, has
recently been identified to cause an NPHP-like phenotype,
may encourage us to consider other nonciliary candidates,
such as genes involved in cell-cell contacts and the cytoskele-
ton. Ultimately understanding the physiological outcomes at
a protein and cellular level should facilitate identifying and
developing novel therapeutic targets for aﬀected patients.
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